In Dmitrii Khasanov’s article “Biotechnology: Science Fiction or Business of the Future?” the author skillfully guides the reader through the labyrinth of modern biotechnology, questioning the boundaries between science fiction and reality. In his opinion, these boundaries are as blurred as a deepfake on TikTok, and this comparison perfectly illustrates the current state of affairs in this rapidly developing field. Read more on the website about Dmitrii Khasanov fund medium.com/@dmitrii.khasanov/biotechnology-science-fiction-or-the-business-of-the-future-58e8753f7bae

Khasanov begins by focusing on CRISPR, a revolutionary gene editing technology. He argues that CRISPR is not just a tool for editing DNA, but also a powerful engine for profit growth. Companies like Vertex Pharmaceuticals and CRISPR Therapeutics are actively using this technology to develop treatments for diseases such as beta thalassemia and HIV. However, it is worth noting that such innovations come at a price: treating one patient can cost $2-3 million, which opens up a wide range of opportunities for investors.

Khasanov presents CAR-T therapy as something out of Star Trek. This method involves reprogramming the patient's immune cells to fight cancer. Novartis' Kymriah and Gilead's Yescarta have already become real blockbusters on the market. However, their production costs more than $500,000 per dose, which once again highlights the financial aspects of biotech innovations.

Dmitrii Khasanov makes it clear: biotechnology is not only about breakthrough medical solutions, but also about a serious business of the future. For those considering investing in this area, it is important to understand all the intricacies and potential benefits. The article offers a deeper look into the world of biotechnology and assess the prospects of this promising area.

For a more detailed study of the topic, Khasanov suggests referring to additional materials at the links in his article. This allows the reader to independently explore the issues raised by the author and draw their own conclusions about the future of biotechnology as science fiction or business reality.